Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker
Merck continues to be the trendsetter to watch in immuno-oncology. On Tuesday the pharma giant nabbed a unique first in the field, grabbing an FDA approval to use Keytruda to fight cancer with a particular biomarker signature of its own.
Specifically, the agency has provided a green light to prescribe Keytruda to fight tumors with a biomarker called microsatellite instability-high or mismatch repair deficient.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.